Wiki-Pi

Search Results for: HIV

5306 interactions found:

Sort by: Relevance Number of Pathways Number of Drugs Number of Diseases
Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
DPP4 and CXCR4 dipeptidyl-peptidase 4 chemokine (C-X-C motif) receptor 4
  • Peptide hormone metabolism
  • Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
  • Incretin synthesis, secretion, and inactivation
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • Signaling by GPCR
  • HIV Infection
  • Class A/1 (Rhodopsin-like receptors)
  • GPCR ligand binding
  • Metabolic disorders of biological oxidation enzymes
  • Early Phase of HIV Life Cycle
  • GPCR downstream signaling
  • HIV Life Cycle
  • Peptide ligand-binding receptors
  • Chemokine receptors bind chemokines
  • G alpha (i) signalling events
  • Binding and entry of HIV virion
  • Atorvastatin
  • Sitagliptin
  • 2-Amino-3-Methyl-1-Pyrrolidin-1-Yl-Butan-1-One
  • 5-(Aminomethyl)-6-(2,4-Dichlorophenyl)-2-(3,5-Dimethoxyphenyl)Pyrimidin-4-Amine
  • Alpha-D-Mannose
  • (2s)-Pyrrolidin-2-Ylmethylamine
  • Iodo-Phenylalanine
  • Diisopropylphosphono Group
  • 1-(1-phenylcyclopentyl)methylamine
  • (S)-2-[(R)-3-amino-4-(2-fluorophenyl)butyryl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
  • Vildagliptin
  • Alogliptin
  • Saxagliptin
  • (1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-PROP-1-YN-1-YLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE
  • N-(TRANS-4-{(1S,2S)-2-AMINO-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-1-METHYL-3-OXOPROPYL}CYCLOHEXYL)-N-METHYLACETAMIDE
  • (2S,3S)-4-cyclopropyl-3-{(3R,5R)-3-[2-fluoro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazolidin-5-yl}-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
  • (2S,3S)-3-{3-[2-chloro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-cyclopentylidene-4-cyclopropyl-1-fluorobutan-2-amine
  • (3R,4R)-4-(pyrrolidin-1-ylcarbonyl)-1-(quinoxalin-2-ylcarbonyl)pyrrolidin-3-amine
  • (7R,8R)-8-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydroimidazo[1,2-a:4,5-c\']dipyridin-7-amine
  • (2S,3S)-3-{3-[4-(METHYLSULFONYL)PHENYL]-1,2,4-OXADIAZOL-5-YL}-1-OXO-1-PYRROLIDIN-1-YLBUTAN-2-AMINE
  • (1S,2R,5S)-5-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-2-(2,4,5-TRIFLUOROPHENYL)CYCLOHEXANAMINE
  • (2R)-4-[(8R)-8-METHYL-2-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[1,5-A]PYRAZIN-7(8H)-YL]-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE
  • (2S,3S)-3-AMINO-4-(3,3-DIFLUOROPYRROLIDIN-1-YL)-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-6-YLCYCLOHEXYL)BUTANAMIDE
  • (2S,3S)-3-AMINO-4-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-5-YLCYCLOHEXYL)BUTANAMIDE
  • (3R)-4-[(3R)-3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL]-3-METHYL-1,4-DIAZEPAN-2-ONE
  • 4\'-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]biphenyl-3-carboxamide
  • (2R,3R)-7-(methylsulfonyl)-3-(2,4,5-trifluorophenyl)-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-2-amine
  • 7-(aminomethyl)-6-(2-chlorophenyl)-1-methyl-1H-benzimidazole-5-carbonitrile
  • (3R)-4-[(3R)-3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL]-3-(2,2,2-TRIFLUOROETHYL)-1,4-DIAZEPAN-2-ONE
  • METHYL 4-{[({[(2R,5S)-5-{[(2S)-2-(AMINOMETHYL)PYRROLIDIN-1-YL]CARBONYL}PYRROLIDIN-2-YL]METHYL}AMINO)CARBONYL]AMINO}BENZOATE
  • (1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-ETHYNYLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE
  • 1-biphenyl-2-ylmethanamine
  • (1S,3S,5S)-2-{(2S)-2-amino-2-[(1R,3S,5R,7S)-3-hydroxytricyclo[3.3.1.1~3,7~]dec-1-yl]acetyl}-2-azabicyclo[3.1.0]hexane-3-carbonitrile
  • (2R)-N-[(2R)-2-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-N-[(5R)-5-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-L-PROLINAMIDE
  • (3R,4S)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE
  • N-({(2S)-1-[(3R)-3-AMINO-4-(2-FLUOROPHENYL)BUTANOYL]PYRROLIDIN-2-YL}METHYL)BENZAMIDE
  • (4R,5R)-5-AMINO-1-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-2-ONE
  • (3R,4S)-1-(3,4-DIMETHOXYPHENYL)-3-(3-METHYLPHENYL)PIPERIDIN-4-AMINE
  • 1-[2-(S)-AMINO-3-BIPHENYL-4-YL-PROPIONYL]-PYRROLIDINE-2-(S)-CARBONITRILE
  • (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE
  • (2R)-4-(2-BENZOYL-1,2-DIAZEPAN-1-YL)-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE
  • (3R,4R)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-3-AMINE
  • 2-(4-{(3S,5S)-5-[(3,3-difluoropyrrolidin-1-yl)carbonyl]pyrrolidin-3-yl}piperazin-1-yl)pyrimidine
  • N-({(2S)-1-[(3R)-3-amino-4-(3-chlorophenyl)butanoyl]pyrrolidin-2-yl}methyl)-3-(methylsulfonyl)benzamide
  • (3R,4S)-1-[6-(6-METHOXYPYRIDIN-3-YL)PYRIMIDIN-4-YL]-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE
  • 6-(4-{(1S,2S)-2-AMINO-1-[(DIMETHYLAMINO)CARBONYL]-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-3-OXOPROPYL}PHENYL)-1H-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-4-IUM
  • 7-BENZYL-1,3-DIMETHYL-8-PIPERAZIN-1-YL-3,7-DIHYDRO-PURINE-2,6-DIONE
  • 2-({2-[(3R)-3-AMINOPIPERIDIN-1-YL]-4-OXOQUINAZOLIN-3(4H)-YL}METHYL)BENZONITRILE
  • 4-[(3R)-3-{[2-(4-FLUOROPHENYL)-2-OXOETHYL]AMINO}BUTYL]BENZAMIDE
  • 2-({8-[(3R)-3-AMINOPIPERIDIN-1-YL]-1,3-DIMETHYL-2,6-DIOXO-1,2,3,6-TETRAHYDRO-7H-PURIN-7-YL}METHYL)BENZONITRILE
  • Linagliptin
  • Framycetin
  • Plerixafor
DPP4 and CD4 dipeptidyl-peptidase 4 CD4 molecule
  • Peptide hormone metabolism
  • Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
  • Incretin synthesis, secretion, and inactivation
  • Vpu mediated degradation of CD4
  • Downstream TCR signaling
  • Generation of second messenger molecules
  • Translocation of ZAP-70 to Immunological synapse
  • Costimulation by the CD28 family
  • Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
  • HIV Infection
  • Host Interactions of HIV factors
  • The role of Nef in HIV-1 replication and disease pathogenesis
  • Early Phase of HIV Life Cycle
  • HIV Life Cycle
  • TCR signaling
  • Alpha-defensins
  • PD-1 signaling
  • Defensins
  • Phosphorylation of CD3 and TCR zeta chains
  • Nef Mediated CD4 Down-regulation
  • Binding and entry of HIV virion
  • Innate Immune System
  • Adaptive Immune System
  • Atorvastatin
  • Sitagliptin
  • 2-Amino-3-Methyl-1-Pyrrolidin-1-Yl-Butan-1-One
  • 5-(Aminomethyl)-6-(2,4-Dichlorophenyl)-2-(3,5-Dimethoxyphenyl)Pyrimidin-4-Amine
  • Alpha-D-Mannose
  • (2s)-Pyrrolidin-2-Ylmethylamine
  • Iodo-Phenylalanine
  • Diisopropylphosphono Group
  • 1-(1-phenylcyclopentyl)methylamine
  • (S)-2-[(R)-3-amino-4-(2-fluorophenyl)butyryl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
  • Vildagliptin
  • Alogliptin
  • Saxagliptin
  • (1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-PROP-1-YN-1-YLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE
  • N-(TRANS-4-{(1S,2S)-2-AMINO-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-1-METHYL-3-OXOPROPYL}CYCLOHEXYL)-N-METHYLACETAMIDE
  • (2S,3S)-4-cyclopropyl-3-{(3R,5R)-3-[2-fluoro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazolidin-5-yl}-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
  • (2S,3S)-3-{3-[2-chloro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-cyclopentylidene-4-cyclopropyl-1-fluorobutan-2-amine
  • (3R,4R)-4-(pyrrolidin-1-ylcarbonyl)-1-(quinoxalin-2-ylcarbonyl)pyrrolidin-3-amine
  • (7R,8R)-8-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydroimidazo[1,2-a:4,5-c\']dipyridin-7-amine
  • (2S,3S)-3-{3-[4-(METHYLSULFONYL)PHENYL]-1,2,4-OXADIAZOL-5-YL}-1-OXO-1-PYRROLIDIN-1-YLBUTAN-2-AMINE
  • (1S,2R,5S)-5-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-2-(2,4,5-TRIFLUOROPHENYL)CYCLOHEXANAMINE
  • (2R)-4-[(8R)-8-METHYL-2-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[1,5-A]PYRAZIN-7(8H)-YL]-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE
  • (2S,3S)-3-AMINO-4-(3,3-DIFLUOROPYRROLIDIN-1-YL)-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-6-YLCYCLOHEXYL)BUTANAMIDE
  • (2S,3S)-3-AMINO-4-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-5-YLCYCLOHEXYL)BUTANAMIDE
  • (3R)-4-[(3R)-3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL]-3-METHYL-1,4-DIAZEPAN-2-ONE
  • 4\'-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]biphenyl-3-carboxamide
  • (2R,3R)-7-(methylsulfonyl)-3-(2,4,5-trifluorophenyl)-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-2-amine
  • 7-(aminomethyl)-6-(2-chlorophenyl)-1-methyl-1H-benzimidazole-5-carbonitrile
  • (3R)-4-[(3R)-3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL]-3-(2,2,2-TRIFLUOROETHYL)-1,4-DIAZEPAN-2-ONE
  • METHYL 4-{[({[(2R,5S)-5-{[(2S)-2-(AMINOMETHYL)PYRROLIDIN-1-YL]CARBONYL}PYRROLIDIN-2-YL]METHYL}AMINO)CARBONYL]AMINO}BENZOATE
  • (1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-ETHYNYLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE
  • 1-biphenyl-2-ylmethanamine
  • (1S,3S,5S)-2-{(2S)-2-amino-2-[(1R,3S,5R,7S)-3-hydroxytricyclo[3.3.1.1~3,7~]dec-1-yl]acetyl}-2-azabicyclo[3.1.0]hexane-3-carbonitrile
  • (2R)-N-[(2R)-2-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-N-[(5R)-5-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-L-PROLINAMIDE
  • (3R,4S)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE
  • N-({(2S)-1-[(3R)-3-AMINO-4-(2-FLUOROPHENYL)BUTANOYL]PYRROLIDIN-2-YL}METHYL)BENZAMIDE
  • (4R,5R)-5-AMINO-1-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-2-ONE
  • (3R,4S)-1-(3,4-DIMETHOXYPHENYL)-3-(3-METHYLPHENYL)PIPERIDIN-4-AMINE
  • 1-[2-(S)-AMINO-3-BIPHENYL-4-YL-PROPIONYL]-PYRROLIDINE-2-(S)-CARBONITRILE
  • (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE
  • (2R)-4-(2-BENZOYL-1,2-DIAZEPAN-1-YL)-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE
  • (3R,4R)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-3-AMINE
  • 2-(4-{(3S,5S)-5-[(3,3-difluoropyrrolidin-1-yl)carbonyl]pyrrolidin-3-yl}piperazin-1-yl)pyrimidine
  • N-({(2S)-1-[(3R)-3-amino-4-(3-chlorophenyl)butanoyl]pyrrolidin-2-yl}methyl)-3-(methylsulfonyl)benzamide
  • (3R,4S)-1-[6-(6-METHOXYPYRIDIN-3-YL)PYRIMIDIN-4-YL]-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE
  • 6-(4-{(1S,2S)-2-AMINO-1-[(DIMETHYLAMINO)CARBONYL]-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-3-OXOPROPYL}PHENYL)-1H-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-4-IUM
  • 7-BENZYL-1,3-DIMETHYL-8-PIPERAZIN-1-YL-3,7-DIHYDRO-PURINE-2,6-DIONE
  • 2-({2-[(3R)-3-AMINOPIPERIDIN-1-YL]-4-OXOQUINAZOLIN-3(4H)-YL}METHYL)BENZONITRILE
  • 4-[(3R)-3-{[2-(4-FLUOROPHENYL)-2-OXOETHYL]AMINO}BUTYL]BENZAMIDE
  • 2-({8-[(3R)-3-AMINOPIPERIDIN-1-YL]-1,3-DIMETHYL-2,6-DIOXO-1,2,3,6-TETRAHYDRO-7H-PURIN-7-YL}METHYL)BENZONITRILE
  • Linagliptin
MAPK14 and CD4 mitogen-activated protein kinase 14 CD4 molecule
  • ADP signalling through P2Y purinoceptor 1
  • Cellular Senescence
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Toll Like Receptor 5 (TLR5) Cascade
  • NOD1/2 Signaling Pathway
  • p38MAPK events
  • MyD88 dependent cascade initiated on endosome
  • Toll Like Receptor 9 (TLR9) Cascade
  • ERK/MAPK targets
  • activated TAK1 mediates p38 MAPK activation
  • Regulation of mRNA stability by proteins that bind AU-rich elements
  • CDO in myogenesis
  • TRIF-mediated TLR3/TLR4 signaling
  • Toll Like Receptor 2 (TLR2) Cascade
  • Platelet homeostasis
  • Activation of PPARGC1A (PGC-1alpha) by phosphorylation
  • Myogenesis
  • Signaling by VEGF
  • Platelet sensitization by LDL
  • Signalling to RAS
  • Toll Like Receptor 4 (TLR4) Cascade
  • Toll Like Receptor 3 (TLR3) Cascade
  • Platelet activation, signaling and aggregation
  • Signalling to ERKs
  • Organelle biogenesis and maintenance
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Signal amplification
  • VEGFA-VEGFR2 Pathway
  • Toll Like Receptor TLR6:TLR2 Cascade
  • Activated TLR4 signalling
  • Activation of the AP-1 family of transcription factors
  • MyD88 cascade initiated on plasma membrane
  • MyD88:Mal cascade initiated on plasma membrane
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • Innate Immune System
  • Signalling by NGF
  • MAP kinase activation in TLR cascade
  • NGF signalling via TRKA from the plasma membrane
  • MyD88-independent cascade
  • Mitochondrial biogenesis
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • DSCAM interactions
  • KSRP destabilizes mRNA
  • Oxidative Stress Induced Senescence
  • Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
  • ERK/MAPK targets
  • MAPK targets/ Nuclear events mediated by MAP kinases
  • Nuclear Events (kinase and transcription factor activation)
  • Vpu mediated degradation of CD4
  • Downstream TCR signaling
  • Generation of second messenger molecules
  • Translocation of ZAP-70 to Immunological synapse
  • Costimulation by the CD28 family
  • Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
  • HIV Infection
  • Host Interactions of HIV factors
  • The role of Nef in HIV-1 replication and disease pathogenesis
  • Early Phase of HIV Life Cycle
  • HIV Life Cycle
  • TCR signaling
  • Alpha-defensins
  • PD-1 signaling
  • Defensins
  • Phosphorylation of CD3 and TCR zeta chains
  • Nef Mediated CD4 Down-regulation
  • Binding and entry of HIV virion
  • Innate Immune System
  • Adaptive Immune System
  • 4-[5-[2-(1-Phenyl-Ethylamino)-Pyrimidin-4-Yl]-1-Methyl-4-(3-Trifluoromethylphenyl)-1h-Imidazol-2-Yl]-Piperidine
  • N-[(3z)-5-Tert-Butyl-2-Phenyl-1,2-Dihydro-3h-Pyrazol-3-Ylidene]-N\'-(4-Chlorophenyl)Urea
  • 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One
  • Inhibitor of P38 Kinase
  • 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine
  • 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine
  • 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea
  • 3-(Benzyloxy)Pyridin-2-Amine
  • 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One
  • 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline
  • 1-(5-Tert-Butyl-2-P-Tolyl-2h-Pyrazol-3-Yl)-3-[4-(2-Morpholin-4-Yl-Ethoxy)-Naphthalen-1-Yl]-Urea
  • 2-Chlorophenol
  • 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole
  • SB220025
  • 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE
  • Triazolopyridine
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
  • N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide
  • 5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)sulfanyl]-6H-pyrimido[1,6-b]pyridazin-6-one
  • N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide
  • 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
  • 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE
  • N-cyclopropyl-2\',6-dimethyl-4\'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
  • 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
  • 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde
  • N-(3-cyanophenyl)-2\'-methyl-5\'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide
  • N-(cyclopropylmethyl)-2\'-methyl-5\'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
  • N~3~-cyclopropyl-N~4~\'-(cyclopropylmethyl)-6-methylbiphenyl-3,4\'-dicarboxamide
  • 3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2H)-yl}-N,4-dimethylbenzamide
  • 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine
  • 2-{4-[5-(4-chlorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxoethanol
  • N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N\'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA
  • N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE
  • 3-FLUORO-N-1H-INDOL-5-YL-5-MORPHOLIN-4-YLBENZAMIDE
  • 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
  • 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA
  • 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM
  • 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE
  • N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide
  • N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide
  • N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide
  • 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine
  • 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE
  • 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
  • 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE
MAPK14 and NUP153 mitogen-activated protein kinase 14 nucleoporin 153kDa
  • ADP signalling through P2Y purinoceptor 1
  • Cellular Senescence
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Toll Like Receptor 5 (TLR5) Cascade
  • NOD1/2 Signaling Pathway
  • p38MAPK events
  • MyD88 dependent cascade initiated on endosome
  • Toll Like Receptor 9 (TLR9) Cascade
  • ERK/MAPK targets
  • activated TAK1 mediates p38 MAPK activation
  • Regulation of mRNA stability by proteins that bind AU-rich elements
  • CDO in myogenesis
  • TRIF-mediated TLR3/TLR4 signaling
  • Toll Like Receptor 2 (TLR2) Cascade
  • Platelet homeostasis
  • Activation of PPARGC1A (PGC-1alpha) by phosphorylation
  • Myogenesis
  • Signaling by VEGF
  • Platelet sensitization by LDL
  • Signalling to RAS
  • Toll Like Receptor 4 (TLR4) Cascade
  • Toll Like Receptor 3 (TLR3) Cascade
  • Platelet activation, signaling and aggregation
  • Signalling to ERKs
  • Organelle biogenesis and maintenance
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Signal amplification
  • VEGFA-VEGFR2 Pathway
  • Toll Like Receptor TLR6:TLR2 Cascade
  • Activated TLR4 signalling
  • Activation of the AP-1 family of transcription factors
  • MyD88 cascade initiated on plasma membrane
  • MyD88:Mal cascade initiated on plasma membrane
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • Innate Immune System
  • Signalling by NGF
  • MAP kinase activation in TLR cascade
  • NGF signalling via TRKA from the plasma membrane
  • MyD88-independent cascade
  • Mitochondrial biogenesis
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • DSCAM interactions
  • KSRP destabilizes mRNA
  • Oxidative Stress Induced Senescence
  • Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
  • ERK/MAPK targets
  • MAPK targets/ Nuclear events mediated by MAP kinases
  • Nuclear Events (kinase and transcription factor activation)
  • Mitotic Prophase
  • HIV Infection
  • Nuclear import of Rev protein
  • Regulatory RNA pathways
  • Rev-mediated nuclear export of HIV RNA
  • Nuclear Envelope Breakdown
  • SLC-mediated transmembrane transport
  • M Phase
  • Influenza Life Cycle
  • HIV Life Cycle
  • Influenza Viral RNA Transcription and Replication
  • Rev-mediated nuclear export of HIV RNA
  • Myoclonic epilepsy of Lafora
  • Glycogen storage diseases
  • Transcriptional regulation by small RNAs
  • Vpr-mediated nuclear import of PICs
  • ISG15 antiviral mechanism
  • Interferon Signaling
  • Host Interactions of HIV factors
  • Nuclear Pore Complex (NPC) Disassembly
  • Regulation of Glucokinase by Glucokinase Regulatory Protein
  • Cytokine Signaling in Immune system
  • Interactions of Vpr with host cellular proteins
  • Interactions of Rev with host cellular proteins
  • Influenza Infection
  • Hexose transport
  • Cell Cycle, Mitotic
  • Late Phase of HIV Life Cycle
  • Antiviral mechanism by IFN-stimulated genes
  • Viral Messenger RNA Synthesis
  • Metabolism of carbohydrates
  • Glucose transport
  • 4-[5-[2-(1-Phenyl-Ethylamino)-Pyrimidin-4-Yl]-1-Methyl-4-(3-Trifluoromethylphenyl)-1h-Imidazol-2-Yl]-Piperidine
  • N-[(3z)-5-Tert-Butyl-2-Phenyl-1,2-Dihydro-3h-Pyrazol-3-Ylidene]-N\'-(4-Chlorophenyl)Urea
  • 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One
  • Inhibitor of P38 Kinase
  • 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine
  • 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine
  • 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea
  • 3-(Benzyloxy)Pyridin-2-Amine
  • 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One
  • 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline
  • 1-(5-Tert-Butyl-2-P-Tolyl-2h-Pyrazol-3-Yl)-3-[4-(2-Morpholin-4-Yl-Ethoxy)-Naphthalen-1-Yl]-Urea
  • 2-Chlorophenol
  • 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole
  • SB220025
  • 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE
  • Triazolopyridine
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
  • N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide
  • 5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)sulfanyl]-6H-pyrimido[1,6-b]pyridazin-6-one
  • N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide
  • 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
  • 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE
  • N-cyclopropyl-2\',6-dimethyl-4\'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
  • 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
  • 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde
  • N-(3-cyanophenyl)-2\'-methyl-5\'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide
  • N-(cyclopropylmethyl)-2\'-methyl-5\'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
  • N~3~-cyclopropyl-N~4~\'-(cyclopropylmethyl)-6-methylbiphenyl-3,4\'-dicarboxamide
  • 3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2H)-yl}-N,4-dimethylbenzamide
  • 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine
  • 2-{4-[5-(4-chlorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxoethanol
  • N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N\'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA
  • N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE
  • 3-FLUORO-N-1H-INDOL-5-YL-5-MORPHOLIN-4-YLBENZAMIDE
  • 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
  • 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA
  • 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM
  • 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE
  • N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide
  • N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide
  • N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide
  • 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine
  • 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE
  • 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
  • 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE
ADRB2 and TSG101 adrenoceptor beta 2, surface tumor susceptibility 101
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • Signaling by GPCR
  • GPCR downstream signaling
  • G alpha (s) signalling events
  • Adrenoceptors
  • Class A/1 (Rhodopsin-like receptors)
  • Amine ligand-binding receptors
  • Metabolic disorders of biological oxidation enzymes
  • GPCR ligand binding
  • Assembly Of The HIV Virion
  • Synthesis And Processing Of GAG, GAGPOL Polyproteins
  • HIV Life Cycle
  • Budding and maturation of HIV virion
  • HIV Infection
  • Endosomal Sorting Complex Required For Transport (ESCRT)
  • Membrane binding and targetting of GAG proteins
  • Late Phase of HIV Life Cycle
  • Betaxolol
  • Metoprolol
  • Norepinephrine
  • Timolol
  • Dipivefrin
  • Sotalol
  • Carteolol
  • Propranolol
  • Labetalol
  • Bisoprolol
  • Epinephrine
  • Orciprenaline
  • Dobutamine
  • Pseudoephedrine
  • Alprenolol
  • Ritodrine
  • Terbutaline
  • Bitolterol
  • Phenoxybenzamine
  • Salmeterol
  • Pindolol
  • Formoterol
  • Salbutamol
  • Isoproterenol
  • Arbutamine
  • Carvedilol
  • Desipramine
  • Acebutolol
  • Nadolol
  • Levobunolol
  • Metipranolol
  • Arformoterol
  • Fenoterol
  • Pirbuterol
  • Bevantolol
  • Penbutolol
  • Ephedra
  • Procaterol
  • Clenbuterol
  • Bambuterol
  • Oxprenolol
  • Nebivolol
  • Indacaterol
  • Asenapine
  • Droxidopa
  • (2S)-1-(9H-Carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol
  • Bopindolol
  • Bupranolol
ADRB2 and RAN adrenoceptor beta 2, surface RAN, member RAS oncogene family
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • Signaling by GPCR
  • GPCR downstream signaling
  • G alpha (s) signalling events
  • Adrenoceptors
  • Class A/1 (Rhodopsin-like receptors)
  • Amine ligand-binding receptors
  • Metabolic disorders of biological oxidation enzymes
  • GPCR ligand binding
  • Transcriptional regulation by small RNAs
  • Metabolism of lipids and lipoproteins
  • Nuclear import of Rev protein
  • HIV Infection
  • Regulatory RNA pathways
  • Rev-mediated nuclear export of HIV RNA
  • Host Interactions of HIV factors
  • MicroRNA (miRNA) biogenesis
  • Influenza Infection
  • Interactions of Rev with host cellular proteins
  • Late Phase of HIV Life Cycle
  • Influenza Life Cycle
  • Regulation of cholesterol biosynthesis by SREBP (SREBF)
  • Export of Viral Ribonucleoproteins from Nucleus
  • HIV Life Cycle
  • Rev-mediated nuclear export of HIV RNA
  • NEP/NS2 Interacts with the Cellular Export Machinery
  • Betaxolol
  • Metoprolol
  • Norepinephrine
  • Timolol
  • Dipivefrin
  • Sotalol
  • Carteolol
  • Propranolol
  • Labetalol
  • Bisoprolol
  • Epinephrine
  • Orciprenaline
  • Dobutamine
  • Pseudoephedrine
  • Alprenolol
  • Ritodrine
  • Terbutaline
  • Bitolterol
  • Phenoxybenzamine
  • Salmeterol
  • Pindolol
  • Formoterol
  • Salbutamol
  • Isoproterenol
  • Arbutamine
  • Carvedilol
  • Desipramine
  • Acebutolol
  • Nadolol
  • Levobunolol
  • Metipranolol
  • Arformoterol
  • Fenoterol
  • Pirbuterol
  • Bevantolol
  • Penbutolol
  • Ephedra
  • Procaterol
  • Clenbuterol
  • Bambuterol
  • Oxprenolol
  • Nebivolol
  • Indacaterol
  • Asenapine
  • Droxidopa
  • (2S)-1-(9H-Carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol
  • Bopindolol
  • Bupranolol
ADRB2 and CD4 adrenoceptor beta 2, surface CD4 molecule
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • Signaling by GPCR
  • GPCR downstream signaling
  • G alpha (s) signalling events
  • Adrenoceptors
  • Class A/1 (Rhodopsin-like receptors)
  • Amine ligand-binding receptors
  • Metabolic disorders of biological oxidation enzymes
  • GPCR ligand binding
  • Vpu mediated degradation of CD4
  • Downstream TCR signaling
  • Generation of second messenger molecules
  • Translocation of ZAP-70 to Immunological synapse
  • Costimulation by the CD28 family
  • Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
  • HIV Infection
  • Host Interactions of HIV factors
  • The role of Nef in HIV-1 replication and disease pathogenesis
  • Early Phase of HIV Life Cycle
  • HIV Life Cycle
  • TCR signaling
  • Alpha-defensins
  • PD-1 signaling
  • Defensins
  • Phosphorylation of CD3 and TCR zeta chains
  • Nef Mediated CD4 Down-regulation
  • Binding and entry of HIV virion
  • Innate Immune System
  • Adaptive Immune System
  • Betaxolol
  • Metoprolol
  • Norepinephrine
  • Timolol
  • Dipivefrin
  • Sotalol
  • Carteolol
  • Propranolol
  • Labetalol
  • Bisoprolol
  • Epinephrine
  • Orciprenaline
  • Dobutamine
  • Pseudoephedrine
  • Alprenolol
  • Ritodrine
  • Terbutaline
  • Bitolterol
  • Phenoxybenzamine
  • Salmeterol
  • Pindolol
  • Formoterol
  • Salbutamol
  • Isoproterenol
  • Arbutamine
  • Carvedilol
  • Desipramine
  • Acebutolol
  • Nadolol
  • Levobunolol
  • Metipranolol
  • Arformoterol
  • Fenoterol
  • Pirbuterol
  • Bevantolol
  • Penbutolol
  • Ephedra
  • Procaterol
  • Clenbuterol
  • Bambuterol
  • Oxprenolol
  • Nebivolol
  • Indacaterol
  • Asenapine
  • Droxidopa
  • (2S)-1-(9H-Carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol
  • Bopindolol
  • Bupranolol
HSP90AA1 and LCK heat shock protein 90kDa alpha (cytosolic), class A member 1 LCK proto-oncogene, Src family tyrosine kinase
  • HSF1 activation
  • Regulatory RNA pathways
  • Signaling by EGFRvIII in Cancer
  • Regulation of PLK1 Activity at G2/M Transition
  • Influenza Life Cycle
  • Influenza Viral RNA Transcription and Replication
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Uptake and actions of bacterial toxins
  • EPH-Ephrin signaling
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • Recruitment of mitotic centrosome proteins and complexes
  • Regulation of actin dynamics for phagocytic cup formation
  • vRNP Assembly
  • Influenza Infection
  • Signaling by ERBB2
  • Signaling by VEGF
  • Signaling by EGFR in Cancer
  • Sema3A PAK dependent Axon repulsion
  • Mitotic G2-G2/M phases
  • Uptake and function of diphtheria toxin
  • PIWI-interacting RNA (piRNA) biogenesis
  • Organelle biogenesis and maintenance
  • Axon guidance
  • Attenuation phase
  • G2/M Transition
  • VEGFA-VEGFR2 Pathway
  • HSF1-dependent transactivation
  • EPHA-mediated growth cone collapse
  • Metabolism of nitric oxide
  • VEGFR2 mediated vascular permeability
  • Loss of Nlp from mitotic centrosomes
  • Scavenging by Class F Receptors
  • eNOS activation and regulation
  • Innate Immune System
  • Semaphorin interactions
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Assembly of the primary cilium
  • Cellular response to heat stress
  • Anchoring of the basal body to the plasma membrane
  • Cell Cycle, Mitotic
  • eNOS activation
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Centrosome maturation
  • Constitutive Signaling by EGFRvIII
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • Nef and signal transduction
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Regulation of KIT signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • CD28 co-stimulation
  • Host Interactions of HIV factors
  • CD28 dependent PI3K/Akt signaling
  • The role of Nef in HIV-1 replication and disease pathogenesis
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • TCR signaling
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • Interleukin-2 signaling
  • PI3K/AKT Signaling in Cancer
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Downstream TCR signaling
  • Costimulation by the CD28 family
  • PIP3 activates AKT signaling
  • HIV Infection
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Nef Mediated CD4 Down-regulation
  • Innate Immune System
  • Signalling by NGF
  • Generation of second messenger molecules
  • Translocation of ZAP-70 to Immunological synapse
  • Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
  • CTLA4 inhibitory signaling
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Cytokine Signaling in Immune system
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • CD28 dependent Vav1 pathway
  • PECAM1 interactions
  • Cell surface interactions at the vascular wall
  • Signaling by FGFR
  • PD-1 signaling
  • GPVI-mediated activation cascade
  • Phosphorylation of CD3 and TCR zeta chains
  • Rifabutin
  • Nedocromil
  • 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine
  • Geldanamycin
  • 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
  • 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine
  • 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid
  • 17-Dmag
  • 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
  • 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine
  • Adenosine-5\'-Diphosphate
  • 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine
  • 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole
  • 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine
  • 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine
  • 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
  • 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine
  • 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
  • N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
  • N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
  • 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE
  • 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE
  • 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
  • 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
  • (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one
  • 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE
  • 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE
  • N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE
  • 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol
  • 4-[4-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-3-METHYL-1H-PYRAZOL-5-YL]-6-ETHYLBENZENE-1,3-DIOL
  • 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol
  • 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE
  • 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine
  • (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime
  • 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-
  • 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol
  • 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol
  • 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide
  • 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
  • 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine
  • 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE
  • 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE
  • Dasatinib
  • {4-[2-Acetylamino-2-(3-Carbamoyl-2-Cyclohexylmethoxy-6,7,8,9-Tetrahydro-5h-Benzocyclohepten-5ylcarbamoyl)-Ethyl]-2-Phosphono-Phenyl}-Phosphonic Acid
  • Staurosporine
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • (4-{2-Acetylamino-2-[1-(3-Carbamoyl-4-Cyclohexylmethoxy-Phenyl)-Ethylcarbamoyl}-Ethyl}-2-Phosphono-Phenoxy)-Acetic Acid
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE
  • 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE
  • N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
  • N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
  • N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine
  • Ponatinib
HSP90AA1 and FYN heat shock protein 90kDa alpha (cytosolic), class A member 1 FYN proto-oncogene, Src family tyrosine kinase
  • HSF1 activation
  • Regulatory RNA pathways
  • Signaling by EGFRvIII in Cancer
  • Regulation of PLK1 Activity at G2/M Transition
  • Influenza Life Cycle
  • Influenza Viral RNA Transcription and Replication
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Uptake and actions of bacterial toxins
  • EPH-Ephrin signaling
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • Recruitment of mitotic centrosome proteins and complexes
  • Regulation of actin dynamics for phagocytic cup formation
  • vRNP Assembly
  • Influenza Infection
  • Signaling by ERBB2
  • Signaling by VEGF
  • Signaling by EGFR in Cancer
  • Sema3A PAK dependent Axon repulsion
  • Mitotic G2-G2/M phases
  • Uptake and function of diphtheria toxin
  • PIWI-interacting RNA (piRNA) biogenesis
  • Organelle biogenesis and maintenance
  • Axon guidance
  • Attenuation phase
  • G2/M Transition
  • VEGFA-VEGFR2 Pathway
  • HSF1-dependent transactivation
  • EPHA-mediated growth cone collapse
  • Metabolism of nitric oxide
  • VEGFR2 mediated vascular permeability
  • Loss of Nlp from mitotic centrosomes
  • Scavenging by Class F Receptors
  • eNOS activation and regulation
  • Innate Immune System
  • Semaphorin interactions
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Assembly of the primary cilium
  • Cellular response to heat stress
  • Anchoring of the basal body to the plasma membrane
  • Cell Cycle, Mitotic
  • eNOS activation
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Centrosome maturation
  • Constitutive Signaling by EGFRvIII
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • DCC mediated attractive signaling
  • Netrin mediated repulsion signals
  • Signaling by EGFRvIII in Cancer
  • Nef and signal transduction
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Regulation of KIT signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • EPH-Ephrin signaling
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • FCGR activation
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • Host Interactions of HIV factors
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • The role of Nef in HIV-1 replication and disease pathogenesis
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • Signaling by VEGF
  • Downstream signal transduction
  • Sema3A PAK dependent Axon repulsion
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Nephrin interactions
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • PI3K/AKT Signaling in Cancer
  • Platelet activation, signaling and aggregation
  • Interleukin-3, 5 and GM-CSF signaling
  • Adaptive Immune System
  • Platelet Adhesion to exposed collagen
  • Axon guidance
  • Costimulation by the CD28 family
  • PIP3 activates AKT signaling
  • HIV Infection
  • VEGFA-VEGFR2 Pathway
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • PI3K events in ERBB2 signaling
  • Regulation of signaling by CBL
  • Downstream signaling of activated FGFR
  • NCAM signaling for neurite out-growth
  • Netrin-1 signaling
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Innate Immune System
  • Signalling by NGF
  • Semaphorin interactions
  • CTLA4 inhibitory signaling
  • Cytokine Signaling in Immune system
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • PECAM1 interactions
  • CD28 dependent Vav1 pathway
  • Signaling by FGFR
  • Cell surface interactions at the vascular wall
  • GPVI-mediated activation cascade
  • Rifabutin
  • Nedocromil
  • 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine
  • Geldanamycin
  • 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
  • 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine
  • 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid
  • 17-Dmag
  • 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
  • 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine
  • Adenosine-5\'-Diphosphate
  • 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine
  • 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole
  • 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine
  • 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine
  • 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
  • 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine
  • 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
  • N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
  • N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
  • 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE
  • 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE
  • 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
  • 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
  • (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one
  • 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE
  • 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE
  • N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE
  • 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol
  • 4-[4-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-3-METHYL-1H-PYRAZOL-5-YL]-6-ETHYLBENZENE-1,3-DIOL
  • 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol
  • 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE
  • 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine
  • (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime
  • 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-
  • 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol
  • 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol
  • 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide
  • 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
  • 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine
  • 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE
  • 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE
  • Dasatinib
  • 1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane
HSP90AA1 and SKP1 heat shock protein 90kDa alpha (cytosolic), class A member 1 S-phase kinase-associated protein 1
  • HSF1 activation
  • Regulatory RNA pathways
  • Signaling by EGFRvIII in Cancer
  • Regulation of PLK1 Activity at G2/M Transition
  • Influenza Life Cycle
  • Influenza Viral RNA Transcription and Replication
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Uptake and actions of bacterial toxins
  • EPH-Ephrin signaling
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • Recruitment of mitotic centrosome proteins and complexes
  • Regulation of actin dynamics for phagocytic cup formation
  • vRNP Assembly
  • Influenza Infection
  • Signaling by ERBB2
  • Signaling by VEGF
  • Signaling by EGFR in Cancer
  • Sema3A PAK dependent Axon repulsion
  • Mitotic G2-G2/M phases
  • Uptake and function of diphtheria toxin
  • PIWI-interacting RNA (piRNA) biogenesis
  • Organelle biogenesis and maintenance
  • Axon guidance
  • Attenuation phase
  • G2/M Transition
  • VEGFA-VEGFR2 Pathway
  • HSF1-dependent transactivation
  • EPHA-mediated growth cone collapse
  • Metabolism of nitric oxide
  • VEGFR2 mediated vascular permeability
  • Loss of Nlp from mitotic centrosomes
  • Scavenging by Class F Receptors
  • eNOS activation and regulation
  • Innate Immune System
  • Semaphorin interactions
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Assembly of the primary cilium
  • Cellular response to heat stress
  • Anchoring of the basal body to the plasma membrane
  • Cell Cycle, Mitotic
  • eNOS activation
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Centrosome maturation
  • Constitutive Signaling by EGFRvIII
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Hedgehog 'off' state
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • truncated APC mutants destabilize the destruction complex
  • TCF7L2 mutants don't bind CTBP
  • Cyclin E associated events during G1/S transition
  • Signaling by Wnt
  • Regulation of PLK1 Activity at G2/M Transition
  • Downstream signaling events of B Cell Receptor (BCR)
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Degradation of beta-catenin by the destruction complex
  • G1/S Transition
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • S33 mutants of beta-catenin aren't phosphorylated
  • Signaling by NOTCH1 in Cancer
  • Prolactin receptor signaling
  • Mitotic G1-G1/S phases
  • truncations of AMER1 destabilize the destruction complex
  • Signaling by NOTCH
  • Host Interactions of HIV factors
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • Regulation of APC/C activators between G1/S and early anaphase
  • S Phase
  • Signaling by ERBB4
  • APC/C-mediated degradation of cell cycle proteins
  • Signaling by Interleukins
  • SCF(Skp2)-mediated degradation of p27/p21
  • deletions in the AMER1 gene destabilize the destruction complex
  • AMER1 mutants destabilize the destruction complex
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Interleukin-1 signaling
  • Cyclin A:Cdk2-associated events at S phase entry
  • SCF(Skp2)-mediated degradation of p27/p21
  • Mitotic G2-G2/M phases
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Adaptive Immune System
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • HIV Infection
  • APC truncation mutants have impaired AXIN binding
  • G2/M Transition
  • APC truncation mutants are not K63 polyubiquitinated
  • S37 mutants of beta-catenin aren't phosphorylated
  • Signaling by NOTCH1
  • Class I MHC mediated antigen processing & presentation
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Vpu mediated degradation of CD4
  • G1 Phase
  • Cytokine Signaling in Immune system
  • Cell Cycle, Mitotic
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Cyclin D associated events in G1
  • Nuclear signaling by ERBB4
  • Activation of NF-kappaB in B cells
  • SCF-beta-TrCP mediated degradation of Emi1
  • Regulation of mitotic cell cycle
  • Signaling by Hedgehog
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Degradation of GLI1 by the proteasome
  • Signaling by WNT in cancer
  • GLI3 is processed to GLI3R by the proteasome
  • Degradation of GLI2 by the proteasome
  • Rifabutin
  • Nedocromil
  • 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine
  • Geldanamycin
  • 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
  • 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine
  • 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid
  • 17-Dmag
  • 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
  • 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine
  • Adenosine-5\'-Diphosphate
  • 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine
  • 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole
  • 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine
  • 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine
  • 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
  • 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine
  • 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
  • N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
  • N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
  • 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE
  • 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE
  • 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
  • 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
  • (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one
  • 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE
  • 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE
  • N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE
  • 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol
  • 4-[4-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-3-METHYL-1H-PYRAZOL-5-YL]-6-ETHYLBENZENE-1,3-DIOL
  • 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol
  • 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE
  • 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine
  • (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime
  • 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-
  • 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol
  • 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol
  • 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide
  • 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
  • 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine
  • 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE
  • 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE
SRC and HLA-A SRC proto-oncogene, non-receptor tyrosine kinase major histocompatibility complex, class I, A
  • Signaling by ERBB2
  • Interferon gamma signaling
  • Interferon Signaling
  • Endosomal/Vacuolar pathway
  • Cytokine Signaling in Immune system
  • Interferon alpha/beta signaling
  • Class I MHC mediated antigen processing & presentation
  • Antigen Presentation: Folding, assembly and peptide loading of class I MHC
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Antigen processing-Cross presentation
  • ER-Phagosome pathway
  • Adaptive Immune System
  • Interferon gamma signaling
  • Interferon Signaling
  • Endosomal/Vacuolar pathway
  • Cytokine Signaling in Immune system
  • Interferon alpha/beta signaling
  • Class I MHC mediated antigen processing & presentation
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Antigen Presentation: Folding, assembly and peptide loading of class I MHC
  • Antigen processing-Cross presentation
  • ER-Phagosome pathway
  • Adaptive Immune System
  • Dasatinib
  • RU84687
  • RU79256
  • N6-Benzyl Adenosine-5\'-Diphosphate
  • RU85493
  • RU78262
  • Phosphonotyrosine
  • Malonic acid
  • RU83876
  • RU90395
  • RU79072
  • RU78783
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • PASBN
  • RU82129
  • PAS219
  • DPI59
  • RU82197
  • Phenylphosphate
  • RU78300
  • RU79073
  • RU82209
  • ISO24
  • RU85053
  • RU78299
  • Oxalic Acid
  • RU78191
  • Citric Acid
  • RU81843
  • 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
  • Purvalanol A
  • Bosutinib
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
  • 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
  • N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
  • (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
  • Ponatinib
SRC and HLA-B SRC proto-oncogene, non-receptor tyrosine kinase major histocompatibility complex, class I, B
  • Signaling by ERBB2
  • Interferon gamma signaling
  • Interferon Signaling
  • Endosomal/Vacuolar pathway
  • Cytokine Signaling in Immune system
  • Interferon alpha/beta signaling
  • Class I MHC mediated antigen processing & presentation
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Antigen Presentation: Folding, assembly and peptide loading of class I MHC
  • Antigen processing-Cross presentation
  • ER-Phagosome pathway
  • Adaptive Immune System
  • Interferon gamma signaling
  • Interferon Signaling
  • Endosomal/Vacuolar pathway
  • Cytokine Signaling in Immune system
  • Interferon alpha/beta signaling
  • Class I MHC mediated antigen processing & presentation
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Antigen Presentation: Folding, assembly and peptide loading of class I MHC
  • Antigen processing-Cross presentation
  • ER-Phagosome pathway
  • Adaptive Immune System
  • Dasatinib
  • RU84687
  • RU79256
  • N6-Benzyl Adenosine-5\'-Diphosphate
  • RU85493
  • RU78262
  • Phosphonotyrosine
  • Malonic acid
  • RU83876
  • RU90395
  • RU79072
  • RU78783
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • PASBN
  • RU82129
  • PAS219
  • DPI59
  • RU82197
  • Phenylphosphate
  • RU78300
  • RU79073
  • RU82209
  • ISO24
  • RU85053
  • RU78299
  • Oxalic Acid
  • RU78191
  • Citric Acid
  • RU81843
  • 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
  • Purvalanol A
  • Bosutinib
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
  • 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
  • N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
  • (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
  • Ponatinib
SRC and NMT1 SRC proto-oncogene, non-receptor tyrosine kinase N-myristoyltransferase 1
  • Signaling by ERBB2
  • Inactivation, recovery and regulation of the phototransduction cascade
  • HIV Life Cycle
  • Visual phototransduction
  • Activation, myristolyation of BID and translocation to mitochondria
  • The phototransduction cascade
  • HIV Infection
  • Programmed Cell Death
  • Diseases associated with visual transduction
  • Late Phase of HIV Life Cycle
  • Intrinsic Pathway for Apoptosis
  • Dasatinib
  • RU84687
  • RU79256
  • N6-Benzyl Adenosine-5\'-Diphosphate
  • RU85493
  • RU78262
  • Phosphonotyrosine
  • Malonic acid
  • RU83876
  • RU90395
  • RU79072
  • RU78783
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • PASBN
  • RU82129
  • PAS219
  • DPI59
  • RU82197
  • Phenylphosphate
  • RU78300
  • RU79073
  • RU82209
  • ISO24
  • RU85053
  • RU78299
  • Oxalic Acid
  • RU78191
  • Citric Acid
  • RU81843
  • 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
  • Purvalanol A
  • Bosutinib
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
  • 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
  • N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
  • (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
  • Ponatinib
SRC and PAK2 SRC proto-oncogene, non-receptor tyrosine kinase p21 protein (Cdc42/Rac)-activated kinase 2
  • Signaling by ERBB2
  • Regulation of PAK-2p34 activity by PS-GAP/RHG10
  • Costimulation by the CD28 family
  • Axon guidance
  • HIV Infection
  • FCERI mediated MAPK activation
  • VEGFA-VEGFR2 Pathway
  • Nef and signal transduction
  • Ephrin signaling
  • Activation of Rac
  • VEGFR2 mediated vascular permeability
  • Programmed Cell Death
  • EPH-Ephrin signaling
  • Innate Immune System
  • Generation of second messenger molecules
  • Semaphorin interactions
  • Apoptotic execution phase
  • CD28 co-stimulation
  • Regulation of activated PAK-2p34 by proteasome mediated degradation
  • Host Interactions of HIV factors
  • The role of Nef in HIV-1 replication and disease pathogenesis
  • CD28 dependent Vav1 pathway
  • Stimulation of the cell death response by PAK-2p34
  • TCR signaling
  • Signaling by VEGF
  • Sema3A PAK dependent Axon repulsion
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by Robo receptor
  • Regulation of Apoptosis
  • Adaptive Immune System
  • Dasatinib
  • RU84687
  • RU79256
  • N6-Benzyl Adenosine-5\'-Diphosphate
  • RU85493
  • RU78262
  • Phosphonotyrosine
  • Malonic acid
  • RU83876
  • RU90395
  • RU79072
  • RU78783
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • PASBN
  • RU82129
  • PAS219
  • DPI59
  • RU82197
  • Phenylphosphate
  • RU78300
  • RU79073
  • RU82209
  • ISO24
  • RU85053
  • RU78299
  • Oxalic Acid
  • RU78191
  • Citric Acid
  • RU81843
  • 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
  • Purvalanol A
  • Bosutinib
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
  • 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
  • N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
  • (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
  • Ponatinib
SRC and PDCD6IP SRC proto-oncogene, non-receptor tyrosine kinase programmed cell death 6 interacting protein
  • Signaling by ERBB2
  • HIV Life Cycle
  • Budding and maturation of HIV virion
  • Uptake and actions of bacterial toxins
  • HIV Infection
  • Uptake and function of anthrax toxins
  • Late Phase of HIV Life Cycle
  • Dasatinib
  • RU84687
  • RU79256
  • N6-Benzyl Adenosine-5\'-Diphosphate
  • RU85493
  • RU78262
  • Phosphonotyrosine
  • Malonic acid
  • RU83876
  • RU90395
  • RU79072
  • RU78783
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • PASBN
  • RU82129
  • PAS219
  • DPI59
  • RU82197
  • Phenylphosphate
  • RU78300
  • RU79073
  • RU82209
  • ISO24
  • RU85053
  • RU78299
  • Oxalic Acid
  • RU78191
  • Citric Acid
  • RU81843
  • 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
  • Purvalanol A
  • Bosutinib
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
  • 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
  • N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
  • (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
  • Ponatinib
ADRA1B and AP2M1 adrenoceptor alpha 1B adaptor-related protein complex 2, mu 1 subunit
  • G alpha (q) signalling events
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • Signaling by GPCR
  • Class A/1 (Rhodopsin-like receptors)
  • Amine ligand-binding receptors
  • Metabolic disorders of biological oxidation enzymes
  • GPCR ligand binding
  • G alpha (q) signalling events
  • GPCR downstream signaling
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Adrenoceptors
  • G alpha (12/13) signalling events
  • Retrograde neurotrophin signalling
  • Axon guidance
  • Gap junction degradation
  • HIV Infection
  • Nef Mediated CD8 Down-regulation
  • L1CAM interactions
  • Signaling by Wnt
  • Signaling by EGFRvIII in Cancer
  • Recycling pathway of L1
  • EPH-ephrin mediated repulsion of cells
  • Gap junction trafficking and regulation
  • MHC class II antigen presentation
  • EPH-Ephrin signaling
  • Nef Mediated CD4 Down-regulation
  • EGFR downregulation
  • Formation of annular gap junctions
  • Signalling by NGF
  • Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
  • Nef mediated downregulation of CD28 cell surface expression
  • Gap junction trafficking
  • Host Interactions of HIV factors
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • The role of Nef in HIV-1 replication and disease pathogenesis
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • beta-catenin independent WNT signaling
  • Signaling by EGFR
  • WNT5A-dependent internalization of FZD4
  • Signaling by EGFR in Cancer
  • PCP/CE pathway
  • Adaptive Immune System
  • Midodrine
  • Ziprasidone
  • Dapiprazole
  • Olanzapine
  • Alfuzosin
  • Clozapine
  • Norepinephrine
  • Phenylephrine
  • Promazine
  • Prazosin
  • Chlorpromazine
  • Doxazosin
  • Labetalol
  • Nicardipine
  • Epinephrine
  • Thioridazine
  • Ergotamine
  • Tamsulosin
  • Methoxamine
  • Trimipramine
  • Risperidone
  • Modafinil
  • Propiomazine
  • Doxepin
  • Nefazodone
  • Terazosin
  • Pergolide
  • Bromocriptine
  • Quetiapine
  • Aripiprazole
  • Lisdexamfetamine
  • Paliperidone
  • Methotrimeprazine
  • Dextroamphetamine
  • Phendimetrazine
  • Propericiazine
  • Acepromazine
  • Thioproperazine
  • Dronedarone
  • Sertindole
  • Silodosin
  • Droxidopa
  • Xylometazoline
AR and SLC25A4 androgen receptor solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
  • Integration of energy metabolism
  • Vpr-mediated induction of apoptosis by mitochondrial outer membrane permeabilization
  • HIV Infection
  • Regulation of insulin secretion
  • Host Interactions of HIV factors
  • Mitochondrial protein import
  • Interactions of Vpr with host cellular proteins
  • Levonorgestrel
  • Spironolactone
  • Flutamide
  • Oxandrolone
  • Testosterone
  • Nilutamide
  • Fludrocortisone
  • Drostanolone
  • Nandrolone phenpropionate
  • Bicalutamide
  • Fluoxymesterone
  • Drospirenone
  • Danazol
  • Testosterone Propionate
  • Delta1-dihydrotestosterone
  • Boldenone
  • Calusterone
  • Flufenamic Acid
  • Dihydrotestosterone
  • (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
  • Methyltrienolone
  • (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
  • Cyproterone
  • Methyltestosterone
  • 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
  • (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
  • 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
  • (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
  • 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
  • (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
  • (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
  • (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
  • S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
  • 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
  • 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
  • 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
  • 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
  • Nandrolone decanoate
  • Enzalutamide
  • Adenosine triphosphate
  • Clodronate
  • [3-(Dodecanoylamino)Propyl](Hydroxy)Dimethylammonium
  • Carboxyatractyloside
  • Cardiolipin
  • Di-Stearoyl-3-Sn-Phosphatidylcholine
AR and CDK7 androgen receptor cyclin-dependent kinase 7
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
  • RNA Polymerase II Promoter Escape
  • Formation of HIV-1 elongation complex containing HIV-1 Tat
  • RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
  • RNA Polymerase I Chain Elongation
  • RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
  • Tat-mediated elongation of the HIV-1 transcript
  • Cyclin E associated events during G1/S transition
  • Formation of transcription-coupled NER (TC-NER) repair complex
  • Dual incision reaction in TC-NER
  • NoRC negatively regulates rRNA expression
  • G1/S Transition
  • Mitotic G1-G1/S phases
  • S Phase
  • Late Phase of HIV Life Cycle
  • Formation of RNA Pol II elongation complex
  • Global Genomic NER (GG-NER)
  • RNA Polymerase II Transcription Initiation And Promoter Clearance
  • Cyclin A:Cdk2-associated events at S phase entry
  • Mitotic G2-G2/M phases
  • Transcription of the HIV genome
  • Nucleotide Excision Repair
  • RNA Polymerase II Transcription
  • RNA Polymerase I Transcription Initiation
  • HIV Infection
  • RNA Polymerase I Promoter Clearance
  • Formation of the Early Elongation Complex
  • G2/M Transition
  • RNA Pol II CTD phosphorylation and interaction with CE
  • RNA Polymerase II Pre-transcription Events
  • HIV Transcription Initiation
  • HIV Life Cycle
  • RNA Pol II CTD phosphorylation and interaction with CE
  • Cyclin A/B1 associated events during G2/M transition
  • RNA Polymerase II HIV Promoter Escape
  • HIV Transcription Elongation
  • Dual incision reaction in GG-NER
  • RNA Polymerase I Transcription
  • mRNA Capping
  • RNA Polymerase I Promoter Escape
  • RNA Polymerase I Transcription Termination
  • G1 Phase
  • Epigenetic regulation of gene expression
  • Negative epigenetic regulation of rRNA expression
  • Cell Cycle, Mitotic
  • Cyclin D associated events in G1
  • Transcription-coupled NER (TC-NER)
  • Formation of HIV elongation complex in the absence of HIV Tat
  • Formation of the HIV-1 Early Elongation Complex
  • Formation of incision complex in GG-NER
  • RNA Polymerase II Transcription Initiation
  • RNA Polymerase II Transcription Elongation
  • Levonorgestrel
  • Spironolactone
  • Flutamide
  • Oxandrolone
  • Testosterone
  • Nilutamide
  • Fludrocortisone
  • Drostanolone
  • Nandrolone phenpropionate
  • Bicalutamide
  • Fluoxymesterone
  • Drospirenone
  • Danazol
  • Testosterone Propionate
  • Delta1-dihydrotestosterone
  • Boldenone
  • Calusterone
  • Flufenamic Acid
  • Dihydrotestosterone
  • (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
  • Methyltrienolone
  • (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
  • Cyproterone
  • Methyltestosterone
  • 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
  • (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
  • 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
  • (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
  • 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
  • (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
  • (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
  • (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
  • S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
  • 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
  • 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
  • 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
  • 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
  • Nandrolone decanoate
  • Enzalutamide
  • Phosphonothreonine
  • Flavopiridol
AR and CDK9 androgen receptor cyclin-dependent kinase 9
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
  • Loss of Function of TGFBR2 in Cancer
  • Formation of HIV-1 elongation complex containing HIV-1 Tat
  • RNA Polymerase II Transcription
  • HIV Infection
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Tat-mediated elongation of the HIV-1 transcript
  • Tat-mediated HIV elongation arrest and recovery
  • TGFBR1 LBD Mutants in Cancer
  • RNA Polymerase II Pre-transcription Events
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • HIV elongation arrest and recovery
  • HIV Life Cycle
  • Generic Transcription Pathway
  • HIV Transcription Elongation
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Host Interactions of HIV factors
  • Loss of Function of SMAD4 in Cancer
  • Interactions of Tat with host cellular proteins
  • TGFBR1 KD Mutants in Cancer
  • Pausing and recovery of Tat-mediated HIV elongation
  • Loss of Function of TGFBR1 in Cancer
  • Late Phase of HIV Life Cycle
  • Formation of RNA Pol II elongation complex
  • Signaling by TGF-beta Receptor Complex
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Pausing and recovery of HIV elongation
  • Formation of HIV elongation complex in the absence of HIV Tat
  • Transcription of the HIV genome
  • SMAD4 MH2 Domain Mutants in Cancer
  • RNA Polymerase II Transcription Elongation
  • Levonorgestrel
  • Spironolactone
  • Flutamide
  • Oxandrolone
  • Testosterone
  • Nilutamide
  • Fludrocortisone
  • Drostanolone
  • Nandrolone phenpropionate
  • Bicalutamide
  • Fluoxymesterone
  • Drospirenone
  • Danazol
  • Testosterone Propionate
  • Delta1-dihydrotestosterone
  • Boldenone
  • Calusterone
  • Flufenamic Acid
  • Dihydrotestosterone
  • (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
  • Methyltrienolone
  • (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
  • Cyproterone
  • Methyltestosterone
  • 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
  • (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
  • 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
  • (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
  • 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
  • (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
  • (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
  • (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
  • S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
  • 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
  • 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
  • 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
  • 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
  • Nandrolone decanoate
  • Enzalutamide
AR and ERCC2 androgen receptor excision repair cross-complementation group 2
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
  • RNA Polymerase II Promoter Escape
  • Formation of HIV-1 elongation complex containing HIV-1 Tat
  • Nucleotide Excision Repair
  • RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
  • RNA Polymerase I Chain Elongation
  • RNA Polymerase II Transcription
  • RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
  • RNA Polymerase I Transcription Initiation
  • RNA Polymerase I Promoter Clearance
  • HIV Infection
  • Formation of the Early Elongation Complex
  • Tat-mediated elongation of the HIV-1 transcript
  • Formation of transcription-coupled NER (TC-NER) repair complex
  • RNA Pol II CTD phosphorylation and interaction with CE
  • RNA Polymerase II Pre-transcription Events
  • Dual incision reaction in TC-NER
  • NoRC negatively regulates rRNA expression
  • HIV Transcription Initiation
  • HIV Life Cycle
  • RNA Pol II CTD phosphorylation and interaction with CE
  • Cytosolic iron-sulfur cluster assembly
  • RNA Polymerase II HIV Promoter Escape
  • HIV Transcription Elongation
  • Dual incision reaction in GG-NER
  • mRNA Capping
  • RNA Polymerase I Transcription
  • RNA Polymerase I Promoter Escape
  • RNA Polymerase I Transcription Termination
  • Epigenetic regulation of gene expression
  • Negative epigenetic regulation of rRNA expression
  • Late Phase of HIV Life Cycle
  • Formation of RNA Pol II elongation complex
  • Global Genomic NER (GG-NER)
  • RNA Polymerase II Transcription Initiation And Promoter Clearance
  • Transcription-coupled NER (TC-NER)
  • Formation of HIV elongation complex in the absence of HIV Tat
  • Formation of the HIV-1 Early Elongation Complex
  • Formation of incision complex in GG-NER
  • RNA Polymerase II Transcription Initiation
  • Transcription of the HIV genome
  • RNA Polymerase II Transcription Elongation
  • Levonorgestrel
  • Spironolactone
  • Flutamide
  • Oxandrolone
  • Testosterone
  • Nilutamide
  • Fludrocortisone
  • Drostanolone
  • Nandrolone phenpropionate
  • Bicalutamide
  • Fluoxymesterone
  • Drospirenone
  • Danazol
  • Testosterone Propionate
  • Delta1-dihydrotestosterone
  • Boldenone
  • Calusterone
  • Flufenamic Acid
  • Dihydrotestosterone
  • (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
  • Methyltrienolone
  • (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
  • Cyproterone
  • Methyltestosterone
  • 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
  • (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
  • 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
  • (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
  • 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
  • (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
  • (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
  • (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
  • S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
  • 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
  • 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
  • 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
  • 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
  • Nandrolone decanoate
  • Enzalutamide

Page 2 out of 266 pages